Skip to content

#双抗/多抗

Today 0 items
Oct 15Thu
  1. biospace.com65

    Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers

    Gilead Sciences has licensed three dual-masked T cell engagers for solid tumors from Vir Biotechnology in a deal worth up to $1.87 billion, including $135 million in upfront and near-term payments. The upfront portion comprises $65 million in cash and a $25 million equity stake, plus $45 million in near-term preclinical milestones, with $1.74 billion in additional milestones possible. Vir will run discovery before handing development of promising assets to Gilead; analysts at H.C. Wainwright await VIR-5818 Phase 1 data in HER2-targeted solid tumors by year-end.

Oct 7Wed
  1. biospace.com40

    Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

    Genmab and AbbVie's bispecific antibody Epkinly, approved in May 2023 for diffuse large B cell lymphoma after at least two prior systemic lines, cut risk of disease progression or death by 51% in a Phase 3 trial when combined with R-CHOP in the frontline setting. In deals, Shionogi bought IntraBio for $2 billion, Novartis committed up to $7.8 billion to Abogen Biosciences, Eli Lilly added up to $870 million with Gate Bioscience, and Sanofi and Regeneron renewed their collaboration with a $1 billion upfront. Sarepta shared Elevidys data in older Duchenne patients at the World Muscle Society meeting, with Jefferies citing upcoming readouts and an FDA decision on Amondys 45 and Vyondys 53.

Oct 2Fri
  1. biopharmadive.com65

    Novartis wagers almost $8B on a Chinese biotech’s RNA drugs

    Novartis will pay Abogen Biosciences $575 million up front in a deal worth as much as $7.8 billion, gaining access to the Chinese biotech's mRNA-encoded drugmaking technology and an option to license ABO2203, a T cell engager targeting CD3 and CD19 being studied in relapsed or refractory B-cell non-Hodgkin lymphoma. Abogen is eligible for up to $7.2 billion in milestone payments, and Novartis could license additional programs. The deal follows a series of Novartis trial failures in September, including three deaths in a paused autoimmune CAR-T trial.

    Why it matters: Large-pharma licensing of Chinese RNA-encoded T cell engager technology at near-record deal value signals a pipeline rebuild after trial failures.

  2. biospace.com64

    Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen

    Novartis will pay Suzhou-based Abogen Biosciences $575 million upfront, with up to around $7.2 billion in milestones plus royalties, to develop ABO2203, an mRNA-encoded CD3xCD19 T cell engager designed to deplete disease-causing B cells in vivo. First-in-human data in nine relapsed or refractory B cell non-Hodgkin lymphoma patients showed no CRS, dose-limiting toxicities or neurological complications, with 100% objective response at the highest dose. Novartis also gains options to license therapies from Abogen's AI-driven RNA platform; target indications were not disclosed.

Sep 15Tue
Aug 15Sat
  1. BioCentury47

    Boulevard: Homing in on B cell biology in autoimmunity

    Deerfield-incubated Boulevard Bio launched with $65 million in aggregate funding to develop B cell-directed therapies for IgA nephropathy and other autoimmune diseases. Its assets include a Phase I long-acting APRIL x BAFF bispecific for IgA nephropathy plus two preclinical autoimmune therapies. Scientific co-founders are CAR T researcher Georg Schett and former Sanofi CSO Frank Nestle.

Aug 14Fri
  1. FiercePharma40

    Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve

    Legend Biotech posted its first profitable quarter, with $63 million in adjusted net income for the three months ended June, as interim CEO Alan Bash discussed expanding Carvykti amid competition from Johnson & Johnson's bispecifics. Taiho and Cullinan Therapeutics' EGFR inhibitor zipalertinib plus chemotherapy succeeded in a phase 3 trial in first-line EGFR exon 20-mutated non-small cell lung cancer, with FDA approval plans ahead. A federal judge granted WuXi AppTec a preliminary injunction blocking the Defense Department's 1260H Chinese military company designation, and China approved Akeso's ivonescimab with chemotherapy for first-line squamous NSCLC.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org